Well, it's a good thing that CUV's drug has an impeccable safety record over decades of use which makes writing about the history of melanocortin drugs and their safety and trial record kinda.....irrelevant. And here's your very post which I've linked at the end where you cite success rates for drugs from P2 and then P3 trials quoting the FDA no less - might be worth quoting those stats which you hold in high regard again when you warn of a competitor drug that is just starting Phase 2. Which is: 33% of drugs make it through Phase 2 and from there about 30% make it through Phase 3 meaning for a drug at the start of Phase 2, it has a 10% chance of getting through both phases to approval.
https://hotcopper.com.au/threads/ann-media-release-first-stroke-patient-with-afamelanotide.6098093/page-11?post_id=53836830
Well, it's a good thing that CUV's drug has an impeccable safety...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.60 |
Change
0.020(0.14%) |
Mkt cap ! $730.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $426.0K | 29.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4 | $14.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 90 | 4 |
View Market Depth
| Last trade - 10.15am 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |